{"id":"W4400029468","doi":"10.1016/j.annonc.2024.05.541","title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System; McGill University","funders":"Daiichi Sankyo Europe; Janssen Research and Development; Genentech; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; MacroGenics; Plexxikon; BeiGene; Mirati Therapeutics; Yuhan; Mersana Therapeutics; PharmaMar; LAM Therapeutics; Astex Pharmaceuticals; Pfizer; Incyte; Merck KGaA; Taiho Pharmaceutical; LG Chem; Regeneron Pharmaceuticals; Sanofi; Amgen; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Osimertinib; Oncology; Lung cancer; Internal medicine; Mutant; Disease; Cancer research; Cancer; Epidermal growth factor receptor; Genetics; Gene","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001420328,0.0002465995,0.00087938,0.0004656512,0.00004375207,0.000008926477,0.0001205169,0.0001262508,0.0005577916],"category_scores_gemma":[0.00004671523,0.0001904304,0.0002409027,0.001052102,0.0001372312,0.00009506573,0.00005187865,0.0002168428,0.000004043006],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002898661,"about_ca_system_score_gemma":0.001739309,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01128197,"about_ca_topic_score_gemma":0.009625205,"domain_scores_codex":[0.9982751,0.00007074852,0.0006057326,0.0004987866,0.0002188003,0.0003308485],"domain_scores_gemma":[0.9984989,0.0004384668,0.0003095436,0.0003711033,0.0001815143,0.000200498],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07984336,0.004727245,0.4889849,0.002992283,0.06684066,0.004617609,0.009016537,0.02828069,0.005489245,0.0001366936,0.004780819,0.3042899],"study_design_scores_gemma":[0.06236364,0.01082723,0.8057357,0.002110243,0.04532471,0.000009846237,0.001949596,0.03401275,0.02103852,0.0002383331,0.01544955,0.0009398815],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9790969,0.01312702,0.0002627673,0.003668453,0.0003427613,0.0006714349,0.00141794,0.00003589046,0.001376827],"genre_scores_gemma":[0.9938185,0.004077771,0.0009379303,0.0002369869,0.00006785315,0.0001757099,0.000474117,0.00003465063,0.0001765325],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3167508,"threshold_uncertainty_score":0.995302,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02074879466258383,"score_gpt":0.3645783786250641,"score_spread":0.3438295839624803,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}